Form 4: Nurix Therapeutics CFO Hans van Houte Sells Shares Under 10b5-1 Trading Plan

Hans van Houte, CFO of Nurix Therapeutics, sold 3,546 shares of common stock on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On November 1, 2024, Hans van Houte, the Chief Financial Officer of Nurix Therapeutics, sold 3,546 shares of the company's common stock.
• The sale was executed at a weighted average price of $24.2762 per share.
• The prices ranged from $24.04 to $24.70.
• This transaction was conducted under a pre-existing Rule 10b5-1 trading plan.
• Following the transaction, van Houte directly owns 33,724 shares of Nurix Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports a transaction under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment towards the company.

Industry Context

Sales by company insiders are a common occurrence and are often viewed in the context of pre-arranged trading plans like Rule 10b5-1, which allows insiders to sell shares at predetermined times to avoid accusations of trading on non-public information.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates